Meiko Pharmaceuticals and Vigorous Biology have reached a strategic cooperation agreement for the joint development of ADC drugs.

According to Mencko Pharmaceuticals, recently, Mencko Pharmaceuticals and Nanjing Pongbo Biotechnology Co., Ltd. officially signed the "ADC Drug Joint Development Strategic Cooperation Agreement." Both parties will fully leverage their respective advantages in the "toxin-linker" platform and "antibody development platform" to jointly discover, research, and develop innovative antibody-drug conjugates for several novel targets.